Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening.
about
Taxol suppresses dynamics of individual microtubules in living human tumor cellsComparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cellsImportance of intracellular pH in determining the uptake and efficacy of the weakly basic chemotherapeutic drug, doxorubicinSuprafenacine, an indazole-hydrazide agent, targets cancer cells through microtubule destabilizationIncreased expression of beta 2-microglobulin in multidrug-resistant tumour cells.Modulation of myogenic differentiation in a human rhabdomyosarcoma cell line by a new derivative of 5-fluorouracil (QF-3602).Gene expression patterns within cell lines are predictive of chemosensitivity.Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance.Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen.Relationship between P-glycoprotein expression and cyclosporin A in kidney. An immunohistological and cell culture study.Impact of mutant β-catenin on ABCB1 expression and therapy response in colon cancer cellsDifferential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.Dietary flavonoid fisetin binds to β-tubulin and disrupts microtubule dynamics in prostate cancer cellsModulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistanceBeyond the imaging: limitations of cellular uptake study in the evaluation of nanoparticles.Multidrug resistance phenotype in the RMS-GR human rhabdomyosarcoma cell line obtained after polychemotherapy.Intracellular levels of two cyclosporin derivatives valspodar (PSC 833) and cyclosporin a closely associated with multidrug resistance-modulating activity in sublines of human colorectal adenocarcinoma HCT-15.Unique amalgamation of primary and secondary structural elements transform peptaibols into potent bioactive cell-penetrating peptides.
P2860
Q24657911-1484A92F-DF57-497B-9BB4-4E9E2DCF51FCQ24793807-C24CABB5-C8D2-43BA-A2DD-40EC5C9C87D2Q28482632-956CB7E6-A95D-4A98-8CCF-7873FACF4A06Q28544463-CBF4CD12-0397-4DE9-8AF7-48822A395B7BQ31088404-F48AE971-556A-46A0-AADA-EDE1448D6E4BQ31442362-68A5543F-26F6-4AF8-9430-CA9F51C48561Q33318982-3F338012-5C41-4729-AD15-E51C57B5A7F9Q33763765-0A08D709-3234-49D1-9A38-69BAFBFF1AD1Q34218136-8E5BCD33-B2E0-49FB-BFD0-CB0C8FE8A9E1Q35796217-45303BAA-3181-460B-AA89-E023C82AF2E6Q35892881-AEFF2AF1-2BBB-4429-AFEE-88D332F9FD79Q35975758-3D9F4AC1-684F-441C-9510-E1852D7310B7Q36060749-358CC5F6-EAB2-4ECE-BA07-A46FA554ACBCQ36136242-CC503D75-84B8-403A-913C-E4E8C7A19F93Q36247616-2887D4F9-6776-4EF5-B1EF-48057D18FE74Q40931773-F21A6806-AB63-4857-A6B3-509E677D441EQ43777030-6C26D26E-8241-4901-A461-A1CED741926DQ47713355-59C51F2C-1759-4C35-9210-53E262080757
P2860
Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
Multidrug-resistant phenotype ...... for anticancer drug screening.
@en
type
label
Multidrug-resistant phenotype ...... for anticancer drug screening.
@en
prefLabel
Multidrug-resistant phenotype ...... for anticancer drug screening.
@en
P2093
P1433
P1476
Multidrug-resistant phenotype ...... for anticancer drug screening.
@en
P2093
Koutsoukos AD
Mullendore LA
Rubinstein LV
Scudiero DA
Stinson SF
P304
P407
P577
1992-06-01T00:00:00Z